Fundus Findings and Thiol-Disulfide Homeostais

Sponsor
Suzan Dogruya (Other)
Overall Status
Recruiting
CT.gov ID
NCT05958927
Collaborator
(none)
60
1
6.6
9

Study Details

Study Description

Brief Summary

Gestational diabetes mellitus is associated with abnormal blood sugar levels throughout pregnancy in women without prior diabetes. Many studies have been conducted on the relationship between diabetes and oxidative stress. In this study, it was aimed to investigate the presence of fundus findings in patients with gestational diabetes and/or impaired blood sugar based on the results of previous studies and to simultaneously investigate the thiol-disulfide homeostasis in the tears of the patients.There was no previous study in the literature on thiol disulfide homeostasis in tears in gestational diabetic patients.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This is a prospective case-control study conducted in 30 pregnant patients diagnosed with gestational diabetes at 24-28 weeks of pregnancy and 30 healthy pregnant women without gestational diabetes in the Uşak Training and Research Hospital Gynecology and Ophthalmology clinic. Glucose tolerance test; If the plasma glucose was 140 mg/dl or higher in the 1st hour after an oral 50 g glucose load, 100 g glucose was added after 8 hours of fasting. The result of 100 gr OGTT was evaluated according to Carpenter and Coustan criteria. Gestational diabetes was diagnosed if two or more of the four glucose levels were abnormal according to the Carpenter and Coustan criteria. Gestational diabetes was diagnosed if the plasma glucose level was 200 mg and above in pregnant women who were loaded with 50 g glucose.

    A total of 60 pregnant women participated in the study. (30 gestational diabetes and 30 healthy pregnant women). Investigators excluded patients with type 1diabetes mellitus and type 2 diabetes mellitus, patient that history of ocular surface disease, topical/systemic medical therapy,with ocular inflamatuar disease such as üveitis. The patients who is healthy pregnant and gestasional diabetes mellitus pregnant were recruit to this study. Controls group included only healthy pregnant.

    Tears analysis is less invasive, safe and accaptable method for research

    All patients underwent a comprehensive ophthalmologic examination that included best-corrected visual acuity, slit-lamp examination, dilated fundus examination and applanation tonometry. Based on the International Clinical DR Disease Severity Scale (ICDRS).

    Tears analysis is less invasive, safe and accaptable method for research. Tear samples, Schirmer paper strips were placed in the lower conjunctival fornix of the right eye for a maximum of 5 minutes. Care was taken not to use tear stimulation, topical anesthetic or other eye drops. Attention was paid to factors such as lighting and room temperature. The ocular surface was not damaged. Tear samples were collected by a single individual (SD). A 15-20 mm test result was considered as enough for biochemical analysis. Schirmer strips were diluted with 500 μl previously cooled PBS (phosphate-buffered saline), and stored in Eppendorf tubes until analysis (-80 °C).

    At the end of the study, fundus findings and tear oxidative stress values of both groups will be compared.ELISA method will be used for determination of tear oxidative stress findings.

    The study followed the tenets of the declaration of Helsinki and was approved by the Uşak üniversitesi Ethics Committee (13.04.2023 / 93-93-04). Written and informed con-sent of participants was obtained for each patient prior to the study.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    60 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Fundus Findings and Thiol-Disulfide Homeostais in Gestational Diabetes
    Actual Study Start Date :
    Apr 13, 2023
    Anticipated Primary Completion Date :
    Oct 1, 2023
    Anticipated Study Completion Date :
    Nov 1, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Thiol-disulfide level in tears in pregnant women with impaired blood sugar and/or gestational DM [24 weeks -28 weeks of pregnant]

      Thiol-disulfide level (µmol/L) is measured by ELISA method in the tears of pregnant women with impaired blood sugar and/or gestational DM.

    2. Retinal nerve fiber thickness and macular thickness in pregnant women with impaired blood sugar and/or gestational DM [24 weeks -28 weeks of pregnant]

      Retinal nerve fiber thickness and macular (µm) are measured by OCT in pregnant women with impaired blood sugar and/or gestational DM

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 40 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Example:
    Inclusion Criteria:
    • Healthy pregnant at 24-28 weeks of pregnancy

    • Pregnant patients diagnosed with gestational diabetes and/or impaired blood sugar at 24-28 weeks of pregnancy

    Exclusion Criteria:
    • Type 1diabetes mellitus,

    • Type 2 diabetes mellitus,

    • Patient that history of ocular surface disease,

    • Topical/systemic medical therapy with ocular inflamatuar disease such as üveitis.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Usak University Medical Faculty Uşak Turkey 64000

    Sponsors and Collaborators

    • Suzan Dogruya

    Investigators

    • Principal Investigator: Suzan Doğruya, Usak University Medical Faculty

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Suzan Dogruya, Doctor, Uşak University
    ClinicalTrials.gov Identifier:
    NCT05958927
    Other Study ID Numbers:
    • Gestational Diabetes
    First Posted:
    Jul 25, 2023
    Last Update Posted:
    Jul 25, 2023
    Last Verified:
    Jul 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 25, 2023